Search Results - "NGUYEN, Aaron N"

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines by Hollenbach, Paul W, Nguyen, Aaron N, Brady, Helen, Williams, Michelle, Ning, Yuhong, Richard, Normand, Krushel, Leslie, Aukerman, Sharon L, Heise, Carla, MacBeth, Kyle J

“…The cytidine nucleoside analogs azacitidine (AZA) and decitabine (DAC) are used for the treatment of patients with myelodysplastic syndromes and acute myeloid…”
Get full text

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors by Navas, Tony A., Mohindru, Mani, Estes, Myka, Ma, Jing Ying, Sokol, Lubomir, Pahanish, Perry, Parmar, Simrit, Haghnazari, Edwin, Zhou, Li, Collins, Robert, Kerr, Irene, Nguyen, Aaron N., Xu, Yin, Platanias, Leonidas C., List, Alan A., Higgins, Linda S., Verma, Amit

“…The myelodysplastic syndromes (MDSs) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias as a result of ineffective…”
Get full text

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells by HIDESHIMA, Teru, PODAR, Klaus, NGUYEN, Aaron N, NAVAS, Tony, MUNSHI, Nikhil C, RICHARDSON, Paul G, HIGGINS, Linda S, ANDERSON, Kenneth C, CHAUHAN, Dharminder, ISHITSUKA, Kenji, MITSIADES, Constantine, TAI, Yu-Tzu, HAMASAKI, Makoto, RAJE, Noopur, HIDESHIMA, Hiromasa, SCHREINER, George

“…Although PS-341 (bortezomib) is a promising agent to improve multiple myeloma (MM) patient outcome, 65% of patients with relapsed and refractory disease do not…”
Get full text

Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment by HAYASHI, Toshiaki, HIDESHIMA, Teru, MURPHY, Alison, CHAUHAN, Dharminder, HIGGINS, Linda S, ANDERSON, Kenneth C, NGUYEN, Aaron N, MUNOZ, Olivier, PODAR, Klaus, HAMASAKI, Makoto, ISHITSUKA, Kenji, YASUI, Hiroshi, RICHARDSON, Paul, CHAKRAVARTY, Sarvajit

“…Purpose: Transforming growth factors (TGFs) have pleiotropic biological effects on tumor cells and their environment. In multiple myeloma (MM), we have…”
Get full text

Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells by Hideshima, Teru, Podar, Klaus, Chauhan, Dharminder, Ishitsuka, Kenji, Mitsiades, Constantine, Tai, Yu-Tzu, Hamasaki, Makoto, Raje, Noopur, Hideshima, Hiromasa, Schreiner, George, Nguyen, Aaron N., Navas, Tony, Munshi, Nikhil C., Richardson, Paul G., Higgins, Linda S., Anderson, Kenneth C.

Get full text

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study by Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, Demirkan, Fatih

“…Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of…”
Get full text

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS by Zhou, Li, Nguyen, Aaron N., Sohal, Davendra, Ying Ma, Jing, Pahanish, Perry, Gundabolu, Krishna, Hayman, Josh, Chubak, Adam, Mo, Yongkai, Bhagat, Tushar D., Das, Bhaskar, Kapoun, Ann M., Navas, Tony A., Parmar, Simrit, Kambhampati, Suman, Pellagatti, Andrea, Braunchweig, Ira, Zhang, Ying, Wickrema, Amittha, Medicherla, Satyanarayana, Boultwood, Jacqueline, Platanias, Leonidas C., Higgins, Linda S., List, Alan F., Bitzer, Markus, Verma, Amit

“…MDS is characterized by ineffective hematopoiesis that leads to peripheral cytopenias. Development of effective treatments has been impeded by limited insight…”
Get full text

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation by Nguyen, Aaron N., Stebbins, Elizabeth G., Henson, Margaret, O'Young, Gilbert, Choi, Sun J., Quon, Diana, Damm, Debby, Reddy, Mamatha, Ma, Jing Y., Haghnazari, Edwin, Kapoun, Ann M., Medicherla, Satyanarayana, Protter, Andy, Schreiner, George F., Kurihara, Noriyoshi, Anderson, Judy, Roodman, G. David, Navas, Tony A., Higgins, Linda S.

“…The multiple myeloma (MM) bone marrow (BM) microenvironment plays a critical role in supporting tumor growth and survival as well as in promoting formation of…”
Get full text

Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines by Nguyen, Aaron N, Hollenbach, Paul W, Richard, Normand, Luna-Moran, Antonio, Brady, Helen, Heise, Carla, MacBeth, Kyle J

“…Azacitidine (AZA) and decitabine (DAC) are cytidine azanucleoside analogs with clinical activity in myelodysplastic syndromes (MDS) and potential activity in…”
Get full text

ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass by Cai, Bin, Nguyen, Aaron N, Zheng, Songmao, Shi, Jianfeng, Liu, Guizhong, Li, Yan, Du, Felix, Luo, Peter, Xu, Jiangchun

“…Binding of the CD47 membrane protein, overexpressed on many tumor types, to the SIRPα inhibitory receptor on myeloid cells results in the inhibition of the…”
Get full text

ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety by Cai, Bin, Nguyen, Aaron N, Zheng, Songmao, Shi, Jianfeng, Liu, Guizhong, Li, Yan, Du, Felix, Frankel, Stanley, Luo, Peter, Xu, Jiangchun

“…Recent clinical data illustrate the effectiveness of CD20xCD3 T cell engagers (TCEs) that redirect the patient's endogenous T cells to eliminate CD20-positive…”
Get full text

Abstract 4257: ADG153-G1, a highly differentiated anti-CD47 IgG1 SAFEbody, demonstrates potent in vivo anti-tumor activities with enhanced ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities by Cai, Bin, Nguyen, Aaron N., Zheng, Songmao, Shi, Jianfeng, Liu, Guizhong, Li, Yan, Du, Felix, Luo, Peter, Xu, Jiangchun

“…Abstract Anti-CD47 antibodies of the IgG4 isotype have shown promising activities in clinical trials for hematologic malignancies, mainly in the combination…”
Get full text

Abstract 1333: Preclinical data supporting the Phase 1 trial design of SENTI-202, a next generation allogeneic logic-gated selective CAR NK cell therapy, engineered to overcome key limitations of first generation cell therapies in AML by Kaveri, Deepika, Chinta, Pearley, Leitner, Elizabeth, Naitmazi, Lawrence, Yucel, Gozde, Tian, Mengxi, Almudhfar, Niran, Deng, Han, Li, Yongshuai, Lam, Alice, Lee, Chen-Ting, Hong, Enping, Emery, Rochelle, Garrison, Brian, Nguyen, Aaron N., Rajangam, Kanya

“…Abstract First generation natural killer (NK) and chimeric antigen receptor (CAR) NK cell products are well-tolerated and have clinical activity (~20-60% CR)…”
Get full text

Abstract 2888: Tumor-targeted CD28 bispecific POWERbody࣪ for safe and synergistic T cell-mediated immunotherapy by Liu, Guizhong, Dai, Zhengxi, Qu, Jiagui, Shi, Jianfeng, Zhao, Qi, Cai, Bin, Nguyen, Aaron N., Zheng, Songmao, Xu, Jiangchun, Li, Yan, Du, Felix, Luo, Peter

“…Abstract Targeting CD28 for systemic T cell activation caused severe cytokine storm and multiorgan failure in an anti-CD28 antibody TGN1412 phase 1 trial…”
Get full text

Abstract 2869: ADG138, a novel HER2×CD3 POWERbody™ integrating bispecific TCE with precision masking to control cytokine release syndrome and on-target off-tumor toxicity for single agent and combination therapies in HER2-expressing solid tumors by Liu, Guizhong, Li, Yan, Dai, Zhengxi, Qu, Jiagui, Shi, Jianfeng, Zhao, Qi, Qu, Linhai, Nguyen, Aaron N., Zheng, Songmao, Xu, Jiangchun, Du, Felix, Luo, Peter

“…Abstract Bispecific T-cell engagers (TCEs) have shown therapeutic promise in treating hematologic cancers. However, their utility in treating solid tumors has…”
Get full text

Abstract 4656: Development of a robust preclinical model for studying the mechanism of azacitidine priming for platin-induced cytotoxicity by Nguyen, Aaron N., Norng, Manith, Luna-Moran, Antonio, MacBeth, Kyle J., DiMartino, Jorge F.

“…Abstract Background: Chemosensitization by azacitidine (AZA) priming has been demonstrated preclinically and is now supported by clinical data, but the…”
Get full text

Abstract 4457: The HDAC inhibitor romidepsin prevents the emergence of drug-tolerant cancer cells by Norng, Manith, Nguyen, Aaron N., DiMartino, Jorge F., MacBeth, Kyle J.

“…Abstract Background: Drug resistance represents a major obstacle to successful cancer treatment. Various resistance mechanisms have been described (e.g., drug…”
Get full text

Abstract 1050: Extended treatment with azacitidine maintains low DNMT1 levels and DNA methylation in MDA-MB-231 cells in vitro and in vivo by Nguyen, Aaron N., Tieu, Quinton, Luna-Moran, Antonio, Melo, Brian, Tong, Zeen, MacBeth, Kyle J.

“…Abstract Background: Azacitidine (AZA) is approved for treatment of patients with myelodysplastic syndromes or WHO-defined acute myeloid leukemia with…”
Get full text

Abstract B217: A Phase I study of CC-486 (oral azacitidine) to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of azacitidine administered alone and in combination with carboplatin or ABI-007 (NAB-paclitaxel) in subjects with solid tumors by Laille, Eric, Nguyen, Aaron N., Chen, Gengxi, Rasco, Drew, LoRusso, Patricia, Von Hoff, Daniel D., Bendell, Johanna, Munster, Pamela, Edenfield, William J., Ramanathan, Ramesh, Gonzalez, Michael B., Blackwood-Chirchir, Anne, DiMartino, Jorge

“…Abstract Background: CC-486 is an orally bioavailable formulation of azacitidine that has demonstrated clinical activity in subjects with Myelodysplastic…”
Get full text

Abstract 191: Azacitidine induces differentiation of acute myeloid leukemia cell lines along the granulocytic/monocytic lineage by Nguyen, Aaron N., Luna-Moran, Antonio, Richard, Normand, Belka, Igor, Brady, Helen, MacBeth, Kyle J.

“…Abstract Acute myeloid leukemia (AML) is characterized by blast cells that are unable to mature into functional, terminally-differentiated hematopoietic cells…”
Get full text